All articles tagged with #alzheimers disease
BGI Genomics and Roche Diagnostics have rolled out blood-based tests for Alzheimer's in China, expanding access to screening and monitoring across Guangzhou, Qingdao, Shenzhen, Wuhan and Boao. BGI says its test is an auxiliary tool and not a standalone diagnosis, while Roche’s pTau181 test has begun clinical use in Boao and could streamline patient pathways and access to treatments such as Leqembi and Kisunla.
A large analysis of about 470,000 people shows that the APOE gene, especially the ε3 and ε4 variants, accounts for most Alzheimer's risk, with ε3 not being neutral and ε2 offering protection. The findings imply APOE-focused therapies could prevent or reduce many cases, though translating this into treatments will be complex and lifestyle factors also influence risk; roughly half of dementia risk could be linked to APOE variations.
Researchers at the University of New Mexico found that OTULIN, an enzyme known for immune regulation, also controls tau production in neurons. By inhibiting OTULIN with a small molecule or knocking out the OTULIN gene, they stopped new tau formation and cleared existing tau in human neuron models, suggesting a novel target for treating Alzheimer’s disease and related tauopathies. The findings also linked OTULIN to RNA metabolism and inflammatory pathways, and researchers note the need to study effects across different brain cell types before pursuing therapies.
A study suggests that changes in daily driving patterns, monitored via vehicle data loggers, can serve as early digital biomarkers for cognitive impairment and dementia, potentially allowing earlier detection and intervention before severe symptoms emerge.
Scientists at Northwestern University discovered a novel compound, NU-9, that can target a previously unknown subtype of brain protein associated with early Alzheimer's disease in mice, potentially allowing for preventative treatment similar to managing high cholesterol. The compound reduces toxic proteins and inflammation, paving the way for future research on its effectiveness in later stages and its potential to control the disease before symptoms appear.
A large Norwegian population study found that the prevalence of Alzheimer’s disease neuropathological changes increases with age, reaching 65.2% in those over 90, with 10% of those over 70 having preclinical AD, highlighting the importance of blood-based biomarkers for large-scale assessment and potential treatment eligibility.
Scientists at Johns Hopkins suggest that small doses of hydrogen sulfide, a gas produced naturally in the body and associated with foul smell, may help protect against Alzheimer's disease by improving brain cell signaling and reducing protein clumping, as demonstrated in mouse studies.
A study published in Science Advances reveals that boosting NAD⁺ levels can restore memory and improve brain function in Alzheimer's disease models by correcting RNA splicing errors through the regulation of EVA1C, offering potential new therapeutic avenues.
Research indicates that walking 3,000 or more steps daily can significantly reduce the risk of cognitive decline and delay the onset of Alzheimer's disease, with benefits increasing up to around 7,500 steps. The study suggests that regular walking helps decrease brain inflammation and tau protein buildup, which are linked to Alzheimer's, and emphasizes that even modest increases in physical activity can be beneficial for brain health.
The study investigates how lymphoid gene expression supports neuroprotective functions of microglia in the human brain, particularly in the context of Alzheimer's disease, using post-mortem samples, induced pluripotent stem cells, and mouse models to explore microglial roles and gene regulation.
During National Alzheimer’s Disease Awareness Month, the President emphasizes the impact of the disease on millions of Americans, highlights efforts to boost research and innovation, and reaffirms commitment to finding a cure and supporting affected families.
A study published in Nature Medicine found that even modest increases in physical activity, such as walking 3,000-7,500 steps daily, can slow cognitive decline and tau protein buildup in older adults at risk for Alzheimer's, suggesting lifestyle changes may delay disease progression.
Recent research uncovers a harmful interaction between amyloid beta and fibrinogen that forms resistant blood clots, contributing to early signs of Alzheimer's disease by damaging blood vessels and synapses, and suggests targeting this complex could offer new therapeutic avenues.
A new study suggests that stranded dolphins may suffer from a form of dementia similar to Alzheimer's disease, potentially caused by exposure to cyanobacterial toxins like BMAA, which can accumulate in marine food chains and may pose risks to human health as well.
A Toronto-based research team proposes that Alzheimer's may be primarily an autoimmune disorder involving the brain's immune response, challenging the traditional view of beta-amyloid as the cause, and emphasizing the need for innovative treatment strategies beyond targeting amyloid plaques.